2616 — CStone Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- HK$7.77bn
- HK$6.36bn
- CNY269.58m
Brief: CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 Million
China's CStone Pharmaceuticals H1 revenue soars on drug sales
Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
Brief: CStone Pharmaceuticals Says Directors And Senior Management Purchase 2.4 Million Shares In June 2026
Brief: CStone Pharmaceuticals Says CEO, Directors, Senior Management Initiate Joint Share Purchase Plan
Brief: CStone Pharmaceuticals Begins Nationwide Commercial Supply Of Locally Manufactured Pralsetinib Capsules
Brief: CStone Pharmaceuticals To Place Aggregate Of 118 Million Shares At Hk$8.97 Per Placing Share
Brief: Cstone Pharmaceuticals Posts FY Revenue Was Rmb269.6 Million
Brief: CStone Pharmaceuticals Says Sugemalimab Gets UK MHRA Approval For Stage III NSCLC
Brief: CStone Pharmaceuticals Says CS2009 Gets FDA IND Clearance For Phase II Trial
Brief: Cstone Pharmaceuticals's CEO Buys Aggregate Of 976,000 Shares From Nov 2025 To Jan 2026
Big Pharma Trump toadying stores up bigger battles
Brief: CStone Pharmaceuticals Says CEO & Management Increase Shareholding In Co By 1 Million Shares Between Oct 20 And 22
Brief: Cstone Pharmaceuticals Says EMA Recommends Approval Of Sugemalimab As Monotherapy
Brief: CStone Pharmaceuticals H1 Net Income RMB -270.2 Million
Brief: Cstone Pharmaceuticals Announces NMPA Approval For Localized Manufacturing Of Gavreto (Pralsetinib) In China
Brief: CStone Pharmaceuticals To Place An Aggregate Of 100 Million Shares At HK$4.72 Per Placing Share
Brief: Cstone Pharmaceuticals Signs Exclusive License Agreement With Istituto Gentili
Brief: Cstone Pharmaceuticals Announces Further Increase In Shareholding By CEO